SG11201404543UA - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents
Pluripotent germ layer origin antigen presenting cancer vaccineInfo
- Publication number
- SG11201404543UA SG11201404543UA SG11201404543UA SG11201404543UA SG11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen presenting
- cancer vaccine
- germ layer
- pluripotent germ
- presenting cancer
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 210000001654 germ layer Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261594304P | 2012-02-02 | 2012-02-02 | |
PCT/US2013/024123 WO2013116505A1 (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201404543UA true SG11201404543UA (en) | 2014-08-28 |
Family
ID=48905824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201404543UA SG11201404543UA (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150064217A1 (en) |
EP (1) | EP2809775B1 (en) |
JP (1) | JP2015506698A (en) |
KR (1) | KR20140143361A (en) |
CN (1) | CN104540937A (en) |
AU (1) | AU2013215116A1 (en) |
CA (1) | CA2863653A1 (en) |
GB (1) | GB2512558A (en) |
HK (2) | HK1202432A1 (en) |
IL (1) | IL233928A0 (en) |
NZ (1) | NZ628292A (en) |
SG (1) | SG11201404543UA (en) |
WO (2) | WO2013116541A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103599528B (en) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | The preparation method of human dendritic cell vaccine |
WO2018070069A1 (en) * | 2016-10-11 | 2018-04-19 | サイトリミック株式会社 | Medicine |
CN110198717A (en) * | 2017-01-11 | 2019-09-03 | 国立研究开发法人国立癌症研究中心 | Immunization therapy medicine |
KR20190115080A (en) * | 2017-02-17 | 2019-10-10 | 에이비타 바이오메디컬, 인크. | Methods for Promoting Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapy Products Using Modified Tumor Cells and Modified Dendritic Cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL140796A0 (en) * | 2001-01-08 | 2002-02-10 | Hadasit Med Res Service | An autologous anti-cancer vaccine |
KR20050027163A (en) * | 2001-09-06 | 2005-03-17 | 노쓰웨스트 바이오써라퓨틱스, 인크. | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
JP5623004B2 (en) * | 2004-10-25 | 2014-11-12 | ベイラー リサーチ インスティテュートBaylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
WO2007016340A2 (en) * | 2005-07-29 | 2007-02-08 | Providence Health System | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
US8097256B2 (en) * | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
-
2013
- 2013-01-31 WO PCT/US2013/024181 patent/WO2013116541A1/en active Application Filing
- 2013-01-31 CA CA2863653A patent/CA2863653A1/en not_active Abandoned
- 2013-01-31 WO PCT/US2013/024123 patent/WO2013116505A1/en active Application Filing
- 2013-01-31 AU AU2013215116A patent/AU2013215116A1/en not_active Abandoned
- 2013-01-31 SG SG11201404543UA patent/SG11201404543UA/en unknown
- 2013-01-31 KR KR1020147024678A patent/KR20140143361A/en not_active Application Discontinuation
- 2013-01-31 JP JP2014555705A patent/JP2015506698A/en active Pending
- 2013-01-31 NZ NZ628292A patent/NZ628292A/en not_active IP Right Cessation
- 2013-01-31 CN CN201380017689.2A patent/CN104540937A/en active Pending
- 2013-01-31 GB GB1414403.4A patent/GB2512558A/en not_active Withdrawn
- 2013-01-31 EP EP13743673.9A patent/EP2809775B1/en not_active Not-in-force
- 2013-01-31 US US14/375,966 patent/US20150064217A1/en not_active Abandoned
-
2014
- 2014-08-03 IL IL233928A patent/IL233928A0/en unknown
-
2015
- 2015-03-24 HK HK15103009.6A patent/HK1202432A1/en unknown
- 2015-10-15 HK HK15110097.4A patent/HK1209455A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB201414403D0 (en) | 2014-10-01 |
EP2809775A4 (en) | 2015-07-01 |
HK1209455A1 (en) | 2016-04-01 |
KR20140143361A (en) | 2014-12-16 |
CN104540937A (en) | 2015-04-22 |
US20150064217A1 (en) | 2015-03-05 |
CA2863653A1 (en) | 2013-08-08 |
JP2015506698A (en) | 2015-03-05 |
EP2809775A1 (en) | 2014-12-10 |
IL233928A0 (en) | 2014-09-30 |
WO2013116541A1 (en) | 2013-08-08 |
EP2809775B1 (en) | 2018-06-13 |
WO2013116505A1 (en) | 2013-08-08 |
AU2013215116A1 (en) | 2014-08-21 |
NZ628292A (en) | 2016-09-30 |
HK1202432A1 (en) | 2015-10-02 |
GB2512558A (en) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207962A1 (en) | Mycobacterial antigen vaccine | |
HK1207967A1 (en) | Vaccine | |
HK1204302A1 (en) | Compositions and methods for cancer immunotherapy | |
EP2714073A4 (en) | In situ antigen-generating cancer vaccine | |
LT3892295T (en) | Individualized vaccines for cancer | |
EP2876161A4 (en) | Vaccine | |
GB201223386D0 (en) | Vaccine | |
EP2868325A4 (en) | Transdermal cancer antigen peptide preparation | |
SG11201500396TA (en) | Tumor vaccination | |
HK1201176A1 (en) | Antigen presenting cancer vaccine | |
GB201003293D0 (en) | Cancer vaccine | |
HK1209455A1 (en) | Pluripotent germ layer origin antigen presenting cancer vaccine | |
HK1202070A1 (en) | Vaccine for tumor immunotherapy | |
EP2869828A4 (en) | Vault immunotherapy | |
ZA201407309B (en) | Antigens and antigen combinations | |
ME03498B (en) | Individualized vaccines for cancer | |
GB201202090D0 (en) | Vaccine | |
GB201107549D0 (en) | Cancer vaccine | |
GB201217321D0 (en) | Vaccine | |
GB201210226D0 (en) | Vaccine | |
GB201206169D0 (en) | Vaccine | |
GB201207383D0 (en) | Antigens and antigen combinations | |
GB201207385D0 (en) | Antigens and antigen combinations | |
GB201216749D0 (en) | Antigen combinations | |
GB201200568D0 (en) | Antigen combinations |